A Nutraceutical Compound Containing a Low Dose of Monacolin K, Polymethoxyflavones, Phenolic Acids, Flavonoids, and Hydroxytyrosol Improves HDL Functionality.

Nutraceutical compound glutathione peroxidase-3 high- density lipoprotein lipoprotein-phospholipase A2 myeloperoxidase

Journal

Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208

Informations de publication

Date de publication:
21 Feb 2023
Historique:
received: 29 07 2022
revised: 19 12 2022
accepted: 19 12 2022
entrez: 24 2 2023
pubmed: 25 2 2023
medline: 25 2 2023
Statut: aheadofprint

Résumé

In earlier studies, it has been observed that 8-week treatment with a novel nutraceutical compound (NC) containing low monacolin K dose, polymethoxyflavones, phenolic acids, flavonoids and hydroxytyrosol improves lipid profile and endothelial function and reduces the level of oxidized low-density lipoprotein (oxLDL). We hypothesize that this effect might be, at least in part, explained by positive modulation exerted by the NC on the atheroprotective function of high-density lipoprotein (HDL). This study aimed to evaluate whether the NC could influence determinants of HDL function. Forty-five subjects with low-moderate dyslipidaemia were enrolled and treated for 8 weeks with the NC, followed by 4 weeks of washout. Blood samples were collected at every time point to evaluate changes in lipid profile, endothelial function, oxLDL, and markers of HDL function, such as the anti-oxidant activities of paraoxonase-1, glutathione peroxidase-3 (Gpx3), lipoprotein-phospholipase A2 (Lp-PLA2), and pro-oxidant activity of myeloperoxidase (MPO). Although the concentration of HDL-C did not change, the activity of Lp-PLA2 significantly decreased upon treatment (-11.6%, p<0.001) and returned to baseline level 4 weeks after the end of treatment. In contrast, Gpx3 increased after treatment (+5%, p<0.01) and remained unvaried after 4 weeks. Both MPO activity and concentration significantly decreased after the washout period (-33 and 32%, p<0.001). For the first time, it was found that the administration of an NC with beneficial effects on lipid homeostasis also positively impacts HDL function by improving the balance between protective and damaging determinants. Further investigation is required to corroborate our findings.

Sections du résumé

BACKGROUND BACKGROUND
In earlier studies, it has been observed that 8-week treatment with a novel nutraceutical compound (NC) containing low monacolin K dose, polymethoxyflavones, phenolic acids, flavonoids and hydroxytyrosol improves lipid profile and endothelial function and reduces the level of oxidized low-density lipoprotein (oxLDL). We hypothesize that this effect might be, at least in part, explained by positive modulation exerted by the NC on the atheroprotective function of high-density lipoprotein (HDL).
AIM OBJECTIVE
This study aimed to evaluate whether the NC could influence determinants of HDL function.
METHODS METHODS
Forty-five subjects with low-moderate dyslipidaemia were enrolled and treated for 8 weeks with the NC, followed by 4 weeks of washout. Blood samples were collected at every time point to evaluate changes in lipid profile, endothelial function, oxLDL, and markers of HDL function, such as the anti-oxidant activities of paraoxonase-1, glutathione peroxidase-3 (Gpx3), lipoprotein-phospholipase A2 (Lp-PLA2), and pro-oxidant activity of myeloperoxidase (MPO).
RESULTS RESULTS
Although the concentration of HDL-C did not change, the activity of Lp-PLA2 significantly decreased upon treatment (-11.6%, p<0.001) and returned to baseline level 4 weeks after the end of treatment. In contrast, Gpx3 increased after treatment (+5%, p<0.01) and remained unvaried after 4 weeks. Both MPO activity and concentration significantly decreased after the washout period (-33 and 32%, p<0.001).
CONCLUSION CONCLUSIONS
For the first time, it was found that the administration of an NC with beneficial effects on lipid homeostasis also positively impacts HDL function by improving the balance between protective and damaging determinants. Further investigation is required to corroborate our findings.

Identifiants

pubmed: 36824007
pii: CVP-EPUB-129663
doi: 10.2174/1570161121666230221142131
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Carlo Cervellati (C)

Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy.

Alessandro Trentini (A)

Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy.

Valentina Rosta (V)

Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy.

Giovanni Zuliani (G)

Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy.

Francesco Vieceli Dalla Sega (F)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Francesca Fortini (F)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Paola Rizzo (P)

Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy.
Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Paolo Cimaglia (P)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.

Gianluca Campo (G)

Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.

Classifications MeSH